UK Edition
AdvertiseSubmit Company
Pharma JournalEvidence-Based Pharmaceutical Intelligence
CLINICAL RESEARCH

iicon

Ophthalmology clinical research and medical affairs services

iicon logo

iicon

Clinical ResearchNorth West England, United Kingdom

Ophthalmology clinical research and medical affairs services

Visit Website

About iicon

Led by Liverpool School of Tropical Medicine and embedded within the North West of England, iiCON (Infection Innovation Consortium) is an open-innovation programme that brings together academic, industry and public-sector partners to accelerate the discovery and development of solutions to infectious disease. Partners include Unilever, LifeArc and Medicines for Malaria Venture, reflecting the consortium's reach across consumer health, life sciences investment and global disease control.

The programme operates across eleven distinct research and development platforms, spanning the full pipeline from early-stage bioactive discovery to clinical evaluation. The Bioactives Library supports the identification of novel antimicrobial agents, while the Hits to Leads platform progresses promising compounds towards new antibiotic candidates. Organoid modelling and advanced AMR modelling platforms underpin mechanistic drug discovery and resistance research, and a dedicated Human Challenge platform enables small-scale clinical trials in a controlled setting.

Diagnostic development sits at the heart of iiCON's translational work. Published case studies document progress on a sputum-free diagnostic for tuberculosis, a scalable test for avian influenza, and a rapid test for antimicrobial resistance, all developed through the consortium's open-innovation microbiome ecosystem model. Further platforms address randomised controlled trials, mapping and modelling, nanotherapeutics, antibody humanisation, and long-acting therapeutics, giving the consortium a broad capability base across the infectious disease space.

A dedicated technology arm, iiTECH, extends this work into applied sensing and quality assurance, with demonstrated projects including lymphatic filariasis sensors and indoor residual spraying quality assurance tools deployed across Africa and India.

Further information is available at infectioninnovation.com.

Areas of Expertise

Antimicrobial ResistanceClinical TrialsDiagnosticsDrug DiscoveryInfectious Disease

Services & Capabilities

Antimicrobial ResistanceClinical TrialsDiagnosticsDrug DiscoveryInfectious Disease
Similar Companies

More in Clinical Research

A

ABX-CRO

ABX-CRO operates as an independent full-service contract research organisation with a declared specialism in neuroscience, oncology and molecular imaging, applying a translational medicine approach to take compounds from early bench research through to clinical bedside application. The organisation's formal name, ABX-CRO advanced pharmaceutical services Forschungsgesellschaft mbH, reflects its German origins, and its footprint has expanded internationally through both organic growth and strategic acquisitions. The service portfolio spans the full drug development continuum. On the clinical side, ABX-CRO provides radiopharmaceutical clinical trials, clinical operations, medical monitoring, pharmacovigilance, data management and biostatistics. Complementing these, the organisation offers imaging and dosimetry services alongside regulatory affairs support, preclinical and pharmacy capabilities, and project design and strategy consultancy. Medical device studies are also within scope. Several milestones mark the company's recent expansion. ABX-CRO acquired ClinSmart LLC, a Pennsylvania-based clinical quality CRO described as well-established, extending its North American presence. In India, the company secured official registration and accreditation with CDSCO as a radiopharmaceutical CRO, enabling it to conduct radiopharmaceutical clinical trials in that market. Recognition from the scientific community has also followed: ABX-CRO and Isotope Technologies Munich jointly received the Marie Curie Award from the European Association of Nuclear Medicine (EANM), acknowledging their collaborative work in the nuclear medicine field. The organisation additionally maintains an India office and a jobs programme, indicating sustained operational investment across multiple geographies. Further information is available at abx-cro.com.

View profile
A

ACM Global Laboratories

ACM Global Laboratories operates across four continents, delivering central laboratory services, bioanalysis, and toxicology to sponsors running clinical trials at every stage of development. With facilities in Rochester (NY), York (UK), Singapore, and Mumbai, the organisation functions as a single integrated laboratory network rather than a collection of regional outposts, giving study teams a consistent standard of science regardless of trial geography. Central Lab and Bioanalytical Capabilities The central lab division handles routine safety testing, biomarker testing, flow cytometry, radiopharmaceutical services, and pathology, alongside the full spectrum of clinical trial testing. Sponsors with urgent timelines can access dedicated rescue and expedite study pathways, reducing the risk that slow laboratory turnaround becomes the critical path on a programme. Sample logistics are supported by customised collection kits and advanced sample tracking, which simplifies the co-ordination burden for site staff and CRO project managers alike. The bioanalytical services portfolio covers large molecule bioanalysis, advanced pharmacokinetic bioanalysis, pharmacodynamic biomarker analysis, controlled substance analysis, and work on novel drug delivery systems. Specialist capability extends to nicotine research and cannabinoid testing, areas that require particular regulatory sensitivity. COVID-19 research studies are also accommodated within the central lab offering. Toxicology and Workplace Testing The toxicology division provides drug monitoring, workplace testing, and reference laboratory testing, serving both clinical development programmes and occupational health requirements. This breadth makes ACM Global Laboratories relevant to pharmaceutical, biotech and corporate clients whose needs span the regulated and non-regulated sectors. Client-facing resources include a self-service portal, the ACM QuikReport tool, and LabStar, a platform that supports site training and sample management. The combination of these digital tools with a global physical footprint positions the organisation well for decentralised and hybrid trial designs that are now common across the industry. ACM marks fifty years of operation, a milestone that underscores the depth of institutional experience behind its service model. Further information is available at acmgloballab.com.

View profile
A

ARC Regulatory

Diagnostic compliance sits at the core of what ARC Regulatory does. Operating as a specialist CRO and regulatory consultancy, the company supports pharmaceutical, diagnostics and laboratory clients navigating the intersection of IVD development, companion diagnostics and clinical research. Headquartered in the United Kingdom, ARC Regulatory positions itself explicitly as a partner for Dx compliance in translational research. The company's service model spans four interconnected pillars. Its regulatory team guides clients through the global regulatory landscape for IVD and CDx development, covering strategy, submissions and ongoing compliance. Clinical services provide IVD and CDx-focused monitoring with a global reach, supporting clinical performance studies from initiation through study close-out. A quality practice delivers QMS auditing, risk management and QMS implementation, while ARC Research Laboratories offers IVD development and validation services using advanced technologies. CRO and Sponsor Delegation for IVD Studies As a full-service CRO, ARC Regulatory guides sponsors through every phase of IVD and CDx clinical development. The company also offers IVD Clinical Study Sponsor Delegation, enabling clients to outsource the initiation and management of IVD studies to ARC's team. This model is particularly relevant to pharma sponsors supporting translational biomarkers in early clinical development, where the company provides proprietary risk-based monitoring of central testing laboratories across the full development life cycle. For diagnostics companies, ARC Regulatory supplies R&D compliance support and full-service CRO capabilities for clinical performance studies, meeting pharmaceutical sponsor expectations. Laboratory clients benefit from analytical testing capabilities, rounding out a broad but IVD-specific service offering. Further information is available at arc-regulatory.co.uk.

View profile
AdvertisementTeksyte LTD

List Your Company

Showcase your company to thousands of pharma professionals.

Submit Listing

Advertise With Us

Reach decision-makers in the pharmaceutical industry.

Learn More

We use cookies and analytics to understand how the site is used and to keep the service free. Choose Accept All to allow this, or Essential Only to use just the cookies we need to keep the site working. You can change your choice any time in our Cookie Policy